OncoGenex Pharmaceuticals Inc. (ACHV) Announces Quarterly Earnings Results

OncoGenex Pharmaceuticals Inc. (NASDAQ:ACHV) released its earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, Bloomberg Earnings reports.

OncoGenex Pharmaceuticals (NASDAQ ACHV) traded up 12.46% during mid-day trading on Friday, hitting $3.34. The stock had a trading volume of 56,087 shares. OncoGenex Pharmaceuticals has a 12 month low of $0.33 and a 12 month high of $4.85. The firm’s 50-day moving average is $1.07 and its 200 day moving average is $0.60. The company’s market cap is $9.14 million.

TRADEMARK VIOLATION WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/12/oncogenex-pharmaceuticals-inc-nasdaqogxi-posts-quarterly-earnings-results-updated.html.

Separately, ValuEngine upgraded OncoGenex Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th.

About OncoGenex Pharmaceuticals

Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.

Earnings History for OncoGenex Pharmaceuticals (NASDAQ:ACHV)

What are top analysts saying about OncoGenex Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OncoGenex Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit